Eiger BioPharmaceuticals, Inc. (EIGR)
Upgrades & Downgrades
Latest EIGR news
7 Cheap But Risky Biotech Stocks
18 January 2023
Biotech stocks remain depressed, nearly two years into a dip that has seen the SPDR S&P Biotech ETF drop nearly 50%.
Best Penny Stocks To Buy? 4 To Watch Before 2023
29 December 2022
Penny stocks to watch before next year. The post Best Penny Stocks To Buy?
Best Penny Stocks To Buy Now? 4 Stocks Under $4 To Watch
28 December 2022
Penny stocks to watch this week. The post Best Penny Stocks To Buy Now?
Eiger BioPharmaceuticals to Host Conference Call to Discuss Phase 3 D-LIVR Study Results of Lonafarn...
7 December 2022
Live Conference Call and Webcast at 8:30 AM ET PALO ALTO, Calif. , Dec. 7, 2022 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (Nasdaq: EIGR), a commercial-stage biopharmaceutical company focused on t...
Eiger BioPharmaceuticals: A Compelling High Beta Story
26 November 2022
Today, we revisit the investment case around Eiger BioPharmaceuticals for the first time in more than a year and a half. Eiger has one product on the market and is rapidly advancing a powerful 'sum of...
Eiger BioPharmaceuticals, Inc. (EIGR) Q3 2022 Earnings Call Transcript
3 November 2022
Eiger BioPharmaceuticals, Inc. (NASDAQ:EIGR ) Q3 2022 Results Conference Call November 3, 2022 4:30 PM ET Company Participants Sarah Mathieson - Senior Vice President, Corporate Affairs David Cory - P...
Eiger BioPharmaceuticals (EIGR) Reports Q3 Loss, Tops Revenue Estimates
3 November 2022
Eiger BioPharma (EIGR) delivered earnings and revenue surprises of -12.73% and 2.39%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Eiger's stock falls 20% after telling investors it won't seek FDA authorization for COVID-19 drug
5 October 2022
Shares of Eiger BioPharmaceuticals Inc. EIGR, -1.20% tumbled 20.4% in premarket trading on Wednesday after the company said it will not pursue emergency authorization of its experimental treatment for...
Eiger BioPharmaceuticals, Inc. (EIGR) CEO David Cory on Q2 2022 Results - Earnings Call Transcript
6 August 2022
Eiger BioPharmaceuticals, Inc. (NASDAQ:EIGR ) Q2 2022 Earnings Conference Call August 4, 2022 4:30 PM ET Company Participants Sarah Mathieson - SVP, Corporate Affairs David Cory - President & CEO Ingr...